CGP-51901 data

Tanox reported Phase IIa results with its anti-IgE monoclonal antibody treatment for allergic rhinitis, which indicated that the drug reduced the severity and duration of nasal symptoms compared to placebo.

As reported at the annual meeting of the American College of Allergy, Asthma and Immunology in Dallas, the multidose blinded trial included 155 patients allergic to mountain cedar pollen. ...